Risk assessment plays key role in long-term treatment of breast cancer

August 12, 2008

HOUSTON - Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reported in the Aug. 12 online issue of the Journal of the National Cancer Institute.

The 2,838 women studied were diagnosed with Stage I through III breast cancers and had been treated with adjuvant systemic therapy (AST), such as chemotherapy and or tamoxifen between 1985 and 2001, and were in the M. D. Anderson Tumor Registry. The patients in the study were five years from the start of their AST and were cancer-free. The researchers calculated the residual or remaining risk of recurrence from the benchmark of five years from the start of AST and determined the factors that contributed to a higher residual risk of recurrence.

"Understandably, one of the most common questions posed by breast cancer survivors is 'What are the chances of it coming back?'," said the study's lead author, Abenaa Brewster, M.D., assistant professor in M. D. Anderson's Department of Clinical Cancer Prevention. "Now we can tell some women within a certain percentage their future risk of recurrence and clinicians may be able to make more informed decisions regarding prescription of extended adjuvant endocrine therapy."

Data analysis revealed that 89 percent of the study populations did not experience a recurrence at five years (approximately 10 years after a woman's initial diagnosis), and 80 percent did not experience a recurrence at 10 years (approximately 15 years after diagnosis).

Brewster commented that, while reassuring for most of the five-year survivors, the percentage of the population who had a recurrence is significant to oncologists.

"The magnitude of risk of recurrence should indicate a need for us to consider extended endocrine treatment for eligible women to further lower their risks," said Brewster. Additionally, the study did not include women who received adjuvant systemic therapy with trastuzamab or five years of aromatase inhibitor treatment and therefore the residual risk of recurrence among those groups of patients could not be determined.

Median follow-up time for women in the study was 28 months. During that time, 216 of the women experienced a recurrence. The five-year residual risks of recurrence for patients with Stage I, II and III cancers were 7 percent, 11 percent and 13 percent respectively. Patients with Stage II or III versus Stage I disease and patients with grade I versus grade III tumors had a higher risk of late recurrence. Patients who had estrogen receptor-positive tumors who received adjuvant endocrine therapy also had a higher risk of recurrence than those with hormone receptor-negative tumors but the difference was not found to meet statistical significance.

The study also indicated a need for the continued development of risk-reduction strategies for pre-menopausal breast cancer survivors because of lack of available therapies in this younger age group. Currently, extended adjuvant endocrine therapy with letrozole (Femara) is available only for post-menopausal patients with hormone receptor positive tumors who have completed five years of tamoxifen therapy.
-end-
Co-authors with Brewster are: Francisco J. Esteva, M.D., Ph.D.; Gabriel N. Hortobagyi, M.D.; Banu K. Arun, M.D.; Aman U. Buzdar, M.D.; Daniel J. Booser, M.D.; Vicente Valero, M.D.; and Shu-Wan C. Kau, B.S.N. of M. D. Anderson's Department of Breast Medical Oncology; Melissa L. Bondy, Ph.D., of M. D. Anderson's Department of Epidemiology; Kristine R. Broglio of M. D. Anderson's Division of Quantitative Sciences; and Cesar A. Santa-Maria of The University of Texas Health Science Center at Houston.



About M. D. Anderson


The University of Texas M. D. Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. M. D. Anderson is one of only 41 Comprehensive Cancer Centers designated by the National Cancer Institute. For six of the past nine years, M. D. Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News and World Report.

University of Texas M. D. Anderson Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.